[go: up one dir, main page]

WO2008008805A3 - Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells - Google Patents

Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells Download PDF

Info

Publication number
WO2008008805A3
WO2008008805A3 PCT/US2007/073202 US2007073202W WO2008008805A3 WO 2008008805 A3 WO2008008805 A3 WO 2008008805A3 US 2007073202 W US2007073202 W US 2007073202W WO 2008008805 A3 WO2008008805 A3 WO 2008008805A3
Authority
WO
WIPO (PCT)
Prior art keywords
target cells
toxins
clostridial
targeting activity
altered targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073202
Other languages
French (fr)
Other versions
WO2008008805A2 (en
Inventor
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to EP07812774A priority Critical patent/EP2038299A2/en
Priority to AU2007272517A priority patent/AU2007272517B2/en
Priority to JP2009519645A priority patent/JP2009543558A/en
Priority to CA002657521A priority patent/CA2657521A1/en
Publication of WO2008008805A2 publication Critical patent/WO2008008805A2/en
Publication of WO2008008805A3 publication Critical patent/WO2008008805A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
PCT/US2007/073202 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells Ceased WO2008008805A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07812774A EP2038299A2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272517A AU2007272517B2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
JP2009519645A JP2009543558A (en) 2006-07-11 2007-07-11 Modified clostridial toxin with enhanced translocation ability and enhanced targeting activity
CA002657521A CA2657521A1 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80705906P 2006-07-11 2006-07-11
US60/807,059 2006-07-11

Publications (2)

Publication Number Publication Date
WO2008008805A2 WO2008008805A2 (en) 2008-01-17
WO2008008805A3 true WO2008008805A3 (en) 2008-04-10

Family

ID=38924120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073202 Ceased WO2008008805A2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells

Country Status (5)

Country Link
EP (1) EP2038299A2 (en)
JP (1) JP2009543558A (en)
AU (1) AU2007272517B2 (en)
CA (1) CA2657521A1 (en)
WO (1) WO2008008805A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US7993656B2 (en) * 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
CA2726092A1 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
CN102112145B (en) 2008-06-12 2014-07-30 辛它可辛有限公司 Suppression of Neuroendocrine Diseases
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
MX2011009606A (en) 2009-03-13 2011-09-28 Allergan Inc Immuno-based retargeted endopeptidase activity assays.
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
CN102822196B (en) 2010-01-25 2014-12-17 阿勒根公司 Methods of intracellular conversion of single-chain proteins into their di-chain form
SG10201506567UA (en) 2010-05-20 2015-10-29 Allergan Inc Degradable Clostridial Toxins
AU2011315962B2 (en) 2010-10-14 2016-06-02 Allergan, Inc. Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP2015534814A (en) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド Recombinant Clostridium botulinum neurotoxin
EP2934571B1 (en) 2012-12-18 2018-05-30 Allergan, Inc. Prophylactic treatment of herpes recurrence
JP6601922B2 (en) * 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド Cationic neurotoxin
US10704035B2 (en) 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
TWI869073B (en) 2018-01-29 2025-01-01 英商艾普森生物製藥有限公司 Non-neuronal snare-cleaving botulinum neurotoxins, in vitro method of cleaving hsnap-23, and use of modified bont/a l-chain protease
US11975055B2 (en) 2018-05-21 2024-05-07 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
WO2022208039A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
AU2022247196A1 (en) 2021-03-30 2023-10-05 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
KR20250069883A (en) 2022-09-30 2025-05-20 입센 바이오팜 리미티드 Clostridium neurotoxin used in the treatment of bladder pain syndrome
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1998007864A1 (en) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Recombinant toxin fragments
WO2001014570A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005011458D1 (en) * 2004-09-01 2009-01-15 Allergan Inc DEGRADABLE CLOSTRIDIENT OXINS
DE102004043009A1 (en) * 2004-09-06 2006-03-23 Toxogen Gmbh Transport protein for introducing chemical compounds into nerve cells
US7993656B2 (en) * 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1998007864A1 (en) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Recombinant toxin fragments
WO2001014570A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2038299A2 *

Also Published As

Publication number Publication date
JP2009543558A (en) 2009-12-10
EP2038299A2 (en) 2009-03-25
AU2007272517A1 (en) 2008-01-17
WO2008008805A2 (en) 2008-01-17
AU2007272517B2 (en) 2013-09-26
CA2657521A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008008805A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008803A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008105901A3 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2006099590A3 (en) Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ATE518882T1 (en) CLOSTRIDIAL TOXINS ACTIVATED WITH CLOSTRIDIENTOXIN
ATE416191T1 (en) DEGRADABLE CLOSTRIDIAL TOXINS
WO2006125000A3 (en) Method for the production of resveratrol in a recombinant oleaginous microorganism
MX369263B (en) Degradable clostridial toxins.
JP2009508489A5 (en)
WO2008053232A3 (en) Mycotoxin-reducing composition
WO2006043178A3 (en) Enzymes
WO2009132220A3 (en) Isoprene synthase variants for improved microbial production of isoprene
WO2008033830A3 (en) Complexity-aware encoding
WO2010014632A3 (en) Methods and compositions for improving the production of products in microorganisms
WO2006102652A3 (en) Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
IL177467A0 (en) Media for clostridium bacterium and processes for obtaining a clostridial toxin
WO2007100922A3 (en) Methods of making polymeric articles and polymeric articles formed thereby
WO2008065060A3 (en) Lipolytic enzyme variants
WO2008061256A3 (en) Tracking usage of portable media device
WO2010138387A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2006124999A3 (en) Method for the production of resveratrol in a recombinant bacterial host cell
BR112012022603A2 (en) highly productive isopropyl alcohol producing bacteria
WO2014063156A3 (en) Modified microorganisms and methods of using same for producing butadiene and one or more of 1,3-butanediol, 1,4-butanediol, and/or 1,3-propanediol
WO2006127642A3 (en) Use of botulinum toxin for treating peritoneal adhesions
Valero et al. Corrigendum to" Kinetic behaviour of proenzymes activation in the presence of different inhibitors for both activating and activated enzymes".[J. Theor. Biol. 245 (2007) 175-192]

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812774

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2657521

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2007812774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007272517

Country of ref document: AU

Ref document number: 2007812774

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009519645

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007272517

Country of ref document: AU

Date of ref document: 20070711

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0715456

Country of ref document: BR

Free format text: APRESENTE FOLHAS DO RELATORIO DESCRITIVO E DO DESENHO ADAPTADOS AO AN NO127/1997.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0715456

Country of ref document: BR

Free format text: PEDIDO RETIRADO POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI 2200 DE 05/03/2013